SCHEMBL2961632

SCHEMBL2961632

C=CC(=O)c1cccc(OC)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.65
CES1 P23141 1/20 0.65
ABCG2 Q9UNQ0 1/20 0.64
PARP1 P09874 1/20 0.61
MAOB P27338 1/20 0.60
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
MAPT P10636 5/20 0.55
LMNA P02545 2/20 0.55
HTT P42858 1/20 0.55
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 3/20 0.54
CYP1A2 P05177 2/20 0.54
CYP3A4 P08684 2/20 0.54
GPR52 Q9Y2T5 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
CYP2D6 P10635 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31167605 0.85 ABCG2 (0.78) CES2CES1ABCG2PARP1MAOB
SCHEMBL2327652 0.84 CES2 (0.67) CES2CES1ABCG2PARP1MAOB
Water SCHEMBL1894563 0.82 CES2 (0.65) CES2CES1ABCG2PARP1MAOB
SCHEMBL14619169 0.82 CES2 (0.65) CES2CES1ABCG2PARP1MAOB
SCHEMBL27278656 0.81 MAPT (0.47) CES2CES1ABCG2PARP1MAOB
SCHEMBL6347273 0.81 ABCG2 (0.58) CES2CES1ABCG2NPC1RAB9A
SCHEMBL18674567 0.81 CES2 (0.62) CES2CES1ABCG2PARP1MAOB
SCHEMBL30641502 0.81 ABCG2 (0.71) CES2CES1ABCG2PARP1MAOB
SCHEMBL21843730 0.81 ABCG2 (0.71) CES2CES1ABCG2PARP1MAOB
SCHEMBL16952755 0.80 NPC1 (0.58) CES2CES1ABCG2PARP1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112321523-B Preparation method and application of oxazolone compound capable of inhibiting bacteria in patient care process 河南科技大学第一附属医院 2021-04-30 CN claimed
CN-112321523-A Preparation method and application of oxazolone compound capable of inhibiting bacteria in patient care process 河南科技大学第一附属医院 2021-02-05 CN claimed
CN-111559985-A Oxazolone compound with bactericidal effect and preparation method thereof 河南科技大学第一附属医院 2020-08-21 CN claimed
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS INC (US) 2025-10-16 US disclosed
CN-112321523-B Preparation method and application of oxazolone compound capable of inhibiting bacteria in patient care process 河南科技大学第一附属医院 2021-04-30 CN disclosed
CN-112321523-A Preparation method and application of oxazolone compound capable of inhibiting bacteria in patient care process 河南科技大学第一附属医院 2021-02-05 CN disclosed
CN-111559985-A Oxazolone compound with bactericidal effect and preparation method thereof 河南科技大学第一附属医院 2020-08-21 CN disclosed
CN-105541582-B The MBH of alpha, beta unsaturated ketone and allyl acetic acid ester reacts 浙江大学 2017-07-18 CN disclosed
US-9663516-B2 Bicyclic-pyrimidinedione compounds MyoKardia, Inc. (US) 2017-05-30 US disclosed
US-9663516-B2 Bicyclic-pyrimidinedione compounds MyoKardia, Inc. (US) 2017-05-30 US disclosed
US-9663516-B2 Bicyclic-pyrimidinedione compounds MyoKardia, Inc. (US) 2017-05-30 US disclosed
EP-1723116-B1 TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS MERZ PHARMA GMBH & CO KGAA (DE) 2008-09-24 EP disclosed
EP-1723116-A2 TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS Merz Pharma GmbH & Co. KGaA (DE) 2006-11-22 EP disclosed
WO-2005082856-A2 TETRAHYDROQUINOLINONES AND THEIR USE AS ANTAGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS MERZ PHARMA GMBH & CO. KGAA (DE) 2005-09-09 WO disclosed
US-20050197361-A1 Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2005-09-08 US disclosed
CN-1015178-B PROCESS AND INTERMEDIATES FOR BETA-LACTAM ANTIBIOTICS HARVARD COLLEGE (US) 1991-12-25 CN disclosed
CN-86104783-A The method for preparing beta-Lactam antibiotics 1987-02-04 CN disclosed
US-4236005-A ANTIANXIETY AMERICAN CYANAMID COMPANY (US) 1980-11-25 US disclosed
US-4209621-A TRANQUILIZERS AMERICAN CYANAMID COMPANY (US) 1980-06-24 US disclosed
US-4178449-A Pyrazolo[1,5-a]pyrimidines and imidazo-[1,5-a]pyrimidines AMERICAN CYANAMID COMPANY (US) 1979-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 CES2 2732/4885CES1 1501/4885ABCG2 1412/4885
US-20050197361-A1 Specific binding is extremely high; low toxicity; high degree of activity; 2-(5-m-Tolyl-thiazol-2-yl )-7,8-dihydro-6H-quinolin-5-one, acute and/or chronic neurological disorders GRM5, GRIK5, GRIN2C CES2 2443/4885CES1 2965/4885ABCG2 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.